Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

ABSTRACT Inhalational anthrax caused by Bacillus anthracis, a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evide...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2019
Materias:	anthrax antitoxins monoclonal antibodies protective antigen toxins Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/bbcf90b9c4804021a29a4fed189b8a61
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bbcf90b9c4804021a29a4fed189b8a61
record_format	dspace
spelling	oai:doaj.org-article:bbcf90b9c4804021a29a4fed189b8a612021-11-15T15:22:19ZQuestionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax10.1128/mSphere.00282-192379-5042https://doaj.org/article/bbcf90b9c4804021a29a4fed189b8a612019-06-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00282-19https://doaj.org/toc/2379-5042ABSTRACT Inhalational anthrax caused by Bacillus anthracis, a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. We argue that inductive reasoning may induce therapeutic bias. We identified anthrax animal model analysis as another bias. Further studies are needed to assess the benefit of anti-PA antibodies in the treatment of inhalational anthrax, while a clearer consensus should be established around what evidence should be proven in an anthrax model.Jean-Nicolas TournierClémence RougeauxFabrice V. BiotPierre L. GoossensAmerican Society for Microbiologyarticleanthraxantitoxinsmonoclonal antibodiesprotective antigentoxinsMicrobiologyQR1-502ENmSphere, Vol 4, Iss 3 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	anthrax antitoxins monoclonal antibodies protective antigen toxins Microbiology QR1-502
spellingShingle	anthrax antitoxins monoclonal antibodies protective antigen toxins Microbiology QR1-502 Jean-Nicolas Tournier Clémence Rougeaux Fabrice V. Biot Pierre L. Goossens Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
description	ABSTRACT Inhalational anthrax caused by Bacillus anthracis, a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. We argue that inductive reasoning may induce therapeutic bias. We identified anthrax animal model analysis as another bias. Further studies are needed to assess the benefit of anti-PA antibodies in the treatment of inhalational anthrax, while a clearer consensus should be established around what evidence should be proven in an anthrax model.
format	article
author	Jean-Nicolas Tournier Clémence Rougeaux Fabrice V. Biot Pierre L. Goossens
author_facet	Jean-Nicolas Tournier Clémence Rougeaux Fabrice V. Biot Pierre L. Goossens
author_sort	Jean-Nicolas Tournier
title	Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
title_short	Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
title_full	Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
title_fullStr	Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
title_full_unstemmed	Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
title_sort	questionable efficacy of therapeutic antibodies in the treatment of anthrax
publisher	American Society for Microbiology
publishDate	2019
url	https://doaj.org/article/bbcf90b9c4804021a29a4fed189b8a61
work_keys_str_mv	AT jeannicolastournier questionableefficacyoftherapeuticantibodiesinthetreatmentofanthrax AT clemencerougeaux questionableefficacyoftherapeuticantibodiesinthetreatmentofanthrax AT fabricevbiot questionableefficacyoftherapeuticantibodiesinthetreatmentofanthrax AT pierrelgoossens questionableefficacyoftherapeuticantibodiesinthetreatmentofanthrax
_version_	1718428029981556736

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

Ejemplares similares